HHS announces savings for 27 Medicare Part B drugs

The US Department of Health and Human Services (HHS), through the Centers for Medicare and Medicaid Services (CMS), has announced 27 prescription drugs for which Part B beneficiary coinsurances may be lower from April 1 to June 30.

These drugs include the inflammatory diseases med Humira (adalimumab), the CAR T-cell therapy Yescarta (axicabtagene ciloleucel) and the antibody-drug conjugate Padcev (enfortumab vedotin).

Under President Joe Biden’s Inflation Reduction Act (IRA), some people with Medicare who take these drugs may save between $2 and $390 per average dose starting April 1, depending on their individual coverage.